Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2005
06/07/2005US6903107 Serine protease inhibitor
06/07/2005US6903106 Nitrogen compounds having improved solubility, bioavailability and stability, used as sedatives, anxiolytics, anticonvulsant, and/ or muscle relaxants for prophylaxis of sleep disorders
06/07/2005US6903098 Use of phthalazine derivatives
06/07/2005US6903095 Phthalimido derivatives and a process for their preparation
06/07/2005US6903090 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal
06/07/2005US6903089 Lactam-substituted pyrazolopyridine derivatives
06/07/2005US6903088 Compounds which inhibit leukocyte adhesion mediated by VLA-4
06/07/2005US6903087 Pyrido cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
06/07/2005US6903086 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
06/07/2005US6903085 Substituted piperidine compounds useful as modulators of chemokine receptor activity
06/07/2005US6902908 Polypeptides, fusion proteins; includes production and use recombinant expression constructs having regulated promoter; mitochondria
06/07/2005US6902742 Pulsatile delivery of methylphenidate to treat attention deficit disorder
06/07/2005US6902739 Administering a stabilized rice bran derivative and a fortification agent; treating bone disorders
06/07/2005US6902734 Also an IL-12 anti-idiotype antibody to the antibody
06/07/2005CA2299036C 4-phenyl-4-heteroarylpiperidine derivatives
06/07/2005CA2209598C Aryl and heteroaryl purine compounds
06/07/2005CA2135783C Substituted (arylalkoxybenzyl) amino-propanamide derivatives and process for their preparation
06/02/2005WO2005049611A1 5-substituted imidazoles
06/02/2005WO2005049601A1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
06/02/2005WO2005049059A1 Perfume for improving the behavior of demented elders
06/02/2005WO2005030332A3 Use of galanthamine and the derivatives thereof in the production of medicaments
06/02/2005WO2005027823A3 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
06/02/2005WO2005026170A3 Uses of neuronal pannexins for therapy and diagnosis in mammals
06/02/2005WO2005020975A3 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
06/02/2005WO2004112762A3 Pharmaceutical formulations of amyloid inhibiting compounds
06/02/2005WO2004041212A3 Apkc isoforms in nervous system disorders and cancer
06/02/2005US20050119499 Cyclic hemiacetal derivative and use thereof
06/02/2005US20050119489 Antidiabetic, anorexigenic, hypotensive, and anticholesterol agents that are synergistically combined with other active agents; obesity, premenstrual tension, hyperlipidemia, myocardial infarction and skin disorders
06/02/2005US20050119458 Transport protein for use in identifying modulator for prevention and treatment of cell proliferative, skin and psychological disorders; anticonvulsants; insecticides; pesticides; anthelmintics
06/02/2005US20050119345 2-Amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives; effective for treating and preventing psychiatric disorders such as schizophrenia, anxiety, bipolar disorder and epilepsy, neurological diseases such as drug dependence, Alzheimer's disease, Huntington's chorea
06/02/2005US20050119334 Neurodegenerative disease; Alzheimer's and Parkinson's disease
06/02/2005US20050119333 Compositions comprising ether compounds and pharmaceutical uses therefor
06/02/2005US20050119327 1-benzyl-5-[(3-methylphenyl)amino]-3-phenyl-1H-indole-2-carboxylic acid; plasminogen activator inhibitor (PAI-1) inhibitor; fibrinolytic system disorder; atrial fibrillation, pulmonary and renal fibrosis, Alzheimer's disease; anticarcinogenic, antiischemic, anticoagulant, antidiabetic
06/02/2005US20050119321 2-substituted-1,3-thiazole compounds
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119308 Remedy for sleep disturbance
06/02/2005US20050119307 Method of treating attention deficit disorders with D-threo methylphenidate
06/02/2005US20050119304 N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(1H-indazol-5-yl)urea; vanilloid receptor (VR1) antagonist; blockage of neurotransmitter release
06/02/2005US20050119293 For therapy of Alzheimer's disease
06/02/2005US20050119285 Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists
06/02/2005US20050119281 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
06/02/2005US20050119280 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives
06/02/2005US20050119277 Benzazole derivatives for the treatment of scleroderma
06/02/2005US20050119267 Diazabicyclo alkane derivatives with nk1 antagonistic activity
06/02/2005US20050119261 Analgesics; neuropathic pain; antiepileptic agents; irritable bowel syndrome; antidepressants; anxiolytic agents; multiple sclerosis; bipolar disorders
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119246 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction
06/02/2005US20050119225 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
06/02/2005US20050119204 Osteopontin-related compositions and methods
06/02/2005US20050119162 Anxiolytic agents; using transferrins; quality of life for cancer patients; antiarthritic agents; antiinflammatory agents; compaction; uniform particle size
06/02/2005US20050118715 Modulation of stem and progenitor cell differentiation, assays, and uses thereof
06/02/2005US20050118696 Methods and means for modulating PGE synthase activity
06/02/2005US20050118573 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
06/02/2005US20050118289 Process for producing fat composition containing hydrophobic components of glycyrrhiza
06/02/2005US20050118263 Composition
06/02/2005US20050118242 Using testosterone; topical applying to skins
06/02/2005US20050118232 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
06/02/2005US20050118202 Keeping the equilibrium moisture content at 10% or above and/or adding ascorbic acid or a salt thereof to stabilize fused nitrogen heterocyclic ring compounds e.g. 5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline,a potential drug for neurodegeneration
06/02/2005US20050118157 Treatment of central nervous system damage
06/02/2005CA2556801A1 Methods and agents for inhibiting dynamin-dependent endocytosis
06/02/2005CA2547842A1 Use of 1,3-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
06/02/2005CA2546620A1 Preparation of 1-aza-2-oxa-dibenzo[e,h]azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
06/02/2005CA2546591A1 Use of 3-aza-1-oxa-dibenzo [e,h] azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
06/02/2005CA2546590A1 Use of 1,2-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
06/02/2005CA2546404A1 Method and composition for treatment or prophylaxis of amyloidosis disorders
06/02/2005CA2546096A1 4-substituted imidazoles
06/02/2005CA2546093A1 5-substituted imidazoles
06/02/2005CA2546007A1 Beta-lactams for treatment of cns disorders
06/02/2005CA2545725A1 Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
06/02/2005CA2545710A1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
06/02/2005CA2544751A1 Macrocyclic lactams and pharmaceutical use thereof
06/02/2005CA2544573A1 Combinations useful for the treatment of neuronal disorders
06/02/2005CA2541293A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia
06/01/2005EP1536011A1 Preventives/remedies for neurodegenerative diseases
06/01/2005EP1535993A1 Biomolecule transfer method using virus envelope and composition and system therefor
06/01/2005EP1535922A1 Pyrrolopyridine derivative and use thereof
06/01/2005EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
06/01/2005EP1535915A1 Furan or thiophene derivative and medicinal use thereof
06/01/2005EP1535909A2 Cyclic amine derivatives and their use as drugs
06/01/2005EP1535902A1 Aminoindan derivatives
06/01/2005EP1535891A1 Remedy
06/01/2005EP1535629A1 Drugs for improving the prognosis of brain injury and a method of screening the same
06/01/2005EP1535616A1 Remedy for integration dysfunction syndrome
06/01/2005EP1535615A1 Composition for nasal absorption
06/01/2005EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF
06/01/2005EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534823A2 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
06/01/2005EP1534807A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid
06/01/2005EP1534753A2 Antibody peg positional isomers, compositions comprising same, and use thereof
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534720A1 Mitochondrially targeted antioxidants
06/01/2005EP1534713A1 Alkyl-substituted pyrazolopyrimidines
06/01/2005EP1534712A2 Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors
06/01/2005EP1534711A1 Phenyl-substituted pyrazolopyrimidines
06/01/2005EP1534710A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/01/2005EP1534709A1 Pyrazolopyrimidines as cyclin dependent kinase inhibitors
06/01/2005EP1534708A2 Purine derivatives and their use as antiproliferative agents
06/01/2005EP1534703A2 Antagonists of melanin concentrating hormone receptor
06/01/2005EP1534694A1 Aryl and heteroaryl morpholine derivatives
1 ... 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 ... 1833